Towards an HIV cure: Science and debate from the International AIDS Society 2013 symposium

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Purcell, Damian F J ^a   Elliott, Julian H ^b,c   Ross, Anna Laura ^d,e   Frater, John ^f,g,h  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c BURNET INSTITUTE   (Australia)

^d ANRS   (France)

^e UNAIDS   (Switzerland)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGS 004; ANTIRETROVIRUS AGENT; BETA CATENIN; CHEMOKINE RECEPTOR CCR5; ECALECTIN; ENTINOSTAT; HISTONE DEACETYLASE 1; KD 247; LYMPHOID ENHANCER FACTOR 1; MARAVIROC; PANOBINOSTAT; RALTEGRAVIR; UNCLASSIFIED DRUG; VORINOSTAT; WNT3A PROTEIN;

ACETYLATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; EDITORIAL; GENE EXPRESSION; GENE SILENCING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; LATENT VIRUS INFECTION; MORBIDITY; MORTALITY; PROMOTER REGION; PROTEIN TARGETING; REDUCED INTENSITY CONDITIONING; REMISSION; RNA TRANSCRIPTION; SYMPOSIUM; T LYMPHOCYTE SUBPOPULATION; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; VIRUS ENTRY; VIRUS LOAD;

ANIMALIA;

ANTI-HIV AGENTS; BIOMEDICAL RESEARCH; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY;

EID: 84887343755     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-134     Document Type: Editorial

References (33)

1. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012, 12:607-614. 10.1038/nri3262, 3595991, 22814509.
2. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011, 117:2791-2799. 10.1182/blood-2010-09-309591, 21148083.
3. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 2009, 360:692-698. 10.1056/NEJMoa0802905, 19213682.
4. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun T-W, Strain M, Richman D, Luzuriaga K. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013, doi:10.1056/NEJMoa1302976.
5. Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hutter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, Deeks SG. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013, 9:e1003347. 10.1371/journal.ppat.1003347, 3649997, 23671416.
6. Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology 2013, 10:67. 10.1186/1742-4690-10-67, 3699421, 23803414.
7. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009, 6:111. 10.1186/1742-4690-6-111, 2797771, 19961595.
8. Cherrier T, Le Douce V, Eilebrecht S, Riclet R, Marban C, Dequiedt F, Goumon Y, Paillart J-C, Mericskay M, Parlakian A, Bausero P, Abbas W, Herbein G, Kurdistani SK, Grana X, Van Driessche B, Schwartz C, Candolfi E, Benecke AG, Van Lint C, Rohr O. CTIP2 is a negative regulator of P-TEFb. Proc Natl Acad Sci 2013, 110:12655-12660. 10.1073/pnas.1220136110, 23852730.
9. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485. 10.1038/nature11286, 3704185, 22837004.
10. Wightman F, Ellenberg P, Churchill M, Lewin SR. HDAC inhibitors in HIV. Immunol Cell Biol 2012, 90:47-54. 10.1038/icb.2011.95, 22083528.
11. Mahmoudi T. The BAF complex and HIV latency. Transcription 2012, 3:171-176. 10.4161/trns.20541, 3654765, 22771990.
12. Kumar A, Zloza A, Moon RT, Watts J, Tenorio AR, Al-Harthi L. Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J Virol 2008, 82:2813-2820. 10.1128/JVI.02498-07, 2258975, 18199649.
13. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300:1295-1297. 10.1126/science.1084238, 12730499.
14. Tandon R, Giret MT, Sengupta D, York VA, Wiznia AA, Rosenberg MG, Kallas EG, Ndhlovu LC, Nixon DF. Age-related expansion of Tim-3 expressing T cells in vertically HIV-1 infected children. PLoS One 2012, 7:e45733. 10.1371/journal.pone.0045733, 3454343, 23029209.
15. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, Loutfy M, Halpenny R, Persad D, Spotts G, Hecht FM, Chun TW, McCune JM, Kaul R, Rini JM, Nixon DF, Ostrowski MA. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008, 205:2763-2779. 10.1084/jem.20081398, 2585847, 19001139.
16. Hazenberg MD, Otto SA, van Rossum AM, Scherpbier HJ, de Groot R, Kuijpers TW, Lange JM, Hamann D, de Boer RJ, Borghans JA, Miedema F. Establishment of the CD4+ T-cell pool in healthy children and untreated children infected with HIV-1. Blood 2004, 104:3513-3519. 10.1182/blood-2004-03-0805, 15297312.
17. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, Lee S, Nanan R, Fazekas de Saint Groth B. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006, 107:2830-2838. 10.1182/blood-2005-06-2403, 16332974.
18. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359:2233-2244. 10.1056/NEJMoa0800971, 2950021, 19020325.
19. Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, Yogev R, Capparelli EV, Chadwick EG. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012, 26:1483-1490. 10.1097/QAD.0b013e3283553638, 3495308, 22555165.
20. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013, 9:e1003211. 10.1371/journal.ppat.1003211, 3597518, 23516360.
21. Hocqueloux L, Avettand-Fenoel V, Jacquot S, Prazuck T, Legac E, Melard A, Niang M, Mille C, Le Moal G, Viard JP, Rouzioux C. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013, 68:1169-1178. 10.1093/jac/dks533, 23335199.
22. Bacchus C, Cheret A, Avettand-Fenoel V, Nembot G, Melard A, Blanc C, Lascoux-Combe C, Slama L, Allegre T, Allavena C, Yazdanpanah Y, Duvivier C, Katlama C, Goujard C, Seksik BC, Leplatois A, Molina JM, Meyer L, Autran B, Rouzioux C. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One 2013, 8:e64219. 10.1371/journal.pone.0064219, 3653877, 23691172.
23. Lecuroux C, Girault I, Cheret A, Versmisse P, Nembot G, Meyer L, Rouzioux C, Pancino G, Venet A, Saez-Cirion A. CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection. PLoS One 2013, 8:e59767. 10.1371/journal.pone.0059767, 3612088, 23555774.
24. Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013, 368:207-217.
25. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, Fisher J, Sierra M, Thomson MM, Najera R, Frank I, Kulkosky J, Pomerantz RJ, Nunnari G. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005, 115:128-137. 539197, 15630452.
26. Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DR. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013, 207:1694-1702. 10.1093/infdis/jit086, 23460751.
27. Dudley DM, Gao Y, Nelson KN, Henry KR, Nankya I, Gibson RM, Arts EJ. A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 2009, 46:458-467. 10.2144/000113119, 19480640.
28. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, Bushman FD, O'Doherty U. Directly infected resting CD4 + T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog 2012, 8:e1002818. 10.1371/journal.ppat.1002818, 3406090, 22911005.
29. Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K, Kaizu M, Izumi Y, Yoshino N, Matsushita S, Higuchi H, Matsui H, Shinohara K, Takeuchi H, Koyanagi Y, Yamamoto N, Honda M. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol 2006, 80:5563-5570. 10.1128/JVI.02095-05, 1472178, 16699037.
30. Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K, Yonemura H, Koyanagi S, Shiosaki K, Higuchi H, Makizumi K, Nakashima T, Osatomi K, Tokiyoshi S, Matsushita S, Yamamoto N, Honda M. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 2006, 80:5552-5562. 10.1128/JVI.02094-05, 1472165, 16699036.
31. Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson MD, Chateau M, Nochi T, Krisko JF, Spagnuolo RA, Margolis DM, Garcia JV. Generation of HIV latency in humanized BLT mice. J Virol 2012, 86:630-634. 10.1128/JVI.06120-11, 3255928, 22013053.
32. Lo B, Grady C. Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS 2013, 8:243-249. 10.1097/COH.0b013e32835ea1c5, 23422260.
33. Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N. Finding a cure for HIV: will it ever be achievable?. J Int AIDS Soc 2011, 14:4. 10.1186/1758-2652-14-4, 3037295, 21255462.